EICHORCondition: Moderate to Severe Crohn's Disease · Sponsor: AstraZeneca
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Research Site | Phoenix, Arizona, United States | — |
| Research Site | Escondido, California, United States | — |
| Research Site | La Jolla, California, United States | — |
| Research Site | Victorville, California, United States | — |
| Research Site | Hamden, Connecticut, United States | — |
| Research Site | Orlando, Florida, United States | — |
| Research Site | Tampa, Florida, United States | — |
| Research Site | Idaho Falls, Idaho, United States | — |
| Research Site | Kansas City, Kansas, United States | — |
| Research Site | Clinton Township, Michigan, United States | — |
| Research Site | Liberty, Missouri, United States | — |
| Research Site | St Louis, Missouri, United States | — |
+ 136 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06450197